MSD (Meso Scale Discovery) is a method similar to ELISA except MSD uses electrochemiluminescence (ECL) as a detection technique as opposed to a colorimetric reaction employed by ELISA. Meso Scale Discovery has developed proprietary technology for the measurement of various molecules in different biological samples including but not limited to serum, plasma, CSF, cell culture supernatants, sputum..

MSD Multiplex immunoassays allow simultaneous detection and quantification of multiple analytes in a single sample from a variety of biological specimens.

V-PLEX Human Cytokine 30/36-Plex Kit

The Human Cytokine 30/36-Plex Panel Kit consists of 4 independent 10-plex panels—Proinflammatory Panel 1 (human), Cytokine Panel 1 (human), TH17 Panel 1 (human), and Chemokine Panel 1 (human)—that detect secreted biomarkers in a variety of tissues and body fluids. The panels are optimized to achieve the highest level of performance from each assay, providing efficient biomarker screening and profiling without compromising performance. These panels are composed of assays against human cytokines and chemokines that are involved in many biological processes such as inflammation, the Th1/Th2 pathway, chemotaxis, the Th17 pathway, angiogenesis, and immune system regulation. As a result of their association with such a wide number of diseases, these assays are the subject of drug discovery projects, diagnostics development, and basic research. The 36-plex panel can be initially used as a screening panel to identify relevant biomarkers that can then be assembled into a custom panel for long-term studies.

• Sample type: Human urine, serum, plasma, and cell culture supernatants.
• Analyte(s): 30 Plex Panel- Eotaxin, Eotaxin-3, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC, TNF-α, TNF-β, VEGF-A. 36 Plex Panel- Eotaxin, Eotaxin-3, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, MIP-3α, TARC, TNF-α, TNF-β, VEGF-A

Analytes in each combinations:

• Angiogenesis Combo 1: FGF (basic), PlGF, Tie‑2, VEGF‑A, VEGF‑D.
  
• CAR-T Cell Combo 1: GM‑CSF, Granzyme A, Granzyme B, IFN‑γ, IL‑2, TNF‑α.
  
• Effector Cell Checkpoint Combo 1: CD27, CD28, CD40L (soluble), CTLA‑4, GITR/TNFRSF18, HAVCR2/TIM‑3, LAG3, OX40/TNFRSF4, PD1 (epitope 1), TIGIT.
  
• Macrophage M1 Combo 1:  IL-1β, IL-6, IL-12p70, IL-18, IL-23, IP-10, MCP-1, MIP-1α, TNF-α.
  
• Macrophage M2 Combo 1:  Eotaxin-2, IL-4, IL-10, IL-13, M-CSF, MDC, TARC.
  
• Target Cell Checkpoint Combo 1: CD276/B7‑H3, GITRL/TNFSF18, PD‑L1 (epitope 1), PD‑L2
  
• Immuno-Oncology Group 1 111-Plex: BAFF, BAFF‑R/TNFRSF13C, BDNF, BCMA/TNFRSF17, CD20, CD27, CD276/B7‑H3, CD28, CD40L (soluble), C‑Peptide, CTACK, CTLA‑4, ENA‑78, Eotaxin, Eotaxin‑2, Eotaxin‑3, EPO, FGF (basic), FGF‑23, FLT3L, Fractalkine, FSH, G‑CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GITR/TNFRSF18, GITRL/TNFSF18, GLP‑1 (active), GLP‑1 (inactive), GM‑CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO‑α, HAVCR2/TIM‑3, I‑309, IFN‑α2a, IFN‑β, IFN‑γ, IL‑1α, IL‑1β, IL‑1RA, IL‑2, IL‑2Rα, IL‑3, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, IL‑9, IL‑10, IL‑12/IL‑23p40, IL‑12p70, IL‑13, IL‑15, IL‑16, IL‑17A, IL‑17A/F, IL‑17C, IL‑17D, IL‑17E/IL‑25, IL‑17F, IL‑18, IL‑21, IL‑22, IL‑23, IL‑27, IL‑29/IFN‑λ1, IL‑31, IL‑33, Insulin, IP‑10, I‑TAC, LAG3, Leptin, LH, MCP‑1, MCP‑2, MCP‑4, M‑CSF, MDC, MIF, MIP‑1α, MIP‑1β, MIP‑5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD‑L1 (epitope 1), PD‑L2, PIGF, PP, Proinsulin, PYY (total), RANKL/TNFSF11, SDF‑1α, Tie‑2, TIGIT, TLR1, TNF‑α, TNF‑β, TPO, TRAIL, TSLP, VEGF‑A, VEGF‑D, YKL‑40.